Dr. Reddy’s Biologics: from a global healthcare company to a trusted biosimilars partner in Europe5

Global experience, European commitment1,4,5,6

  • Established in 1984
    by Dr. Anji Reddy
  • Truly Global
    Footprint1
  • 8.2% of the
    Global Revenue
    Invested in R&D
  • Including API,
    Finished
    Formulations
    and Biologics
  • Access our
    Therapies
    Every Year

Established in 1998, Dr. Reddy’s Biologics division has developed a complete suite of capabilities from cell line development to commercial manufacturing.6

We are committed to making innovative medicines accessible worldwide, with the focus on Europe.1

  • 27+ years of Experience in Biologics6
  • >1 M patients treated with
    Dr. Reddy’s Biologics worldwide6
  • Since 2022 on European market

4 brands already launched in Europe 4 products in pipeline to be launched within 5 years in oncology, immunology, skeletal health & CNS

Long-term presence on German market7

  • beta pharm7